ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

Other companies developing cell therapies or antibodies targeting CD19 include ADC Therapeutics (ADCT), Allogene Therapeutics (ALLO), AstraZeneca (AZN), Autolus Therapeutics (AUTL), Bristol-Myers ...

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD ...

IKSUDA holds pipelines such as LCB14 (HER2-ADC), LCB73 (CD19-ADC), and through the transfer of LigaChem Biosciences' material technology, IKS04 (CanAg-ADC), IKS012 (FRα-ADC), among others.

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April ...